Zoetis Inc. (NYSE:ZTS) Shares Sold by Verde Servicos Internacionais S.A.

Verde Servicos Internacionais S.A. lessened its stake in Zoetis Inc. (NYSE:ZTS) by 8.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,847 shares of the company’s stock after selling 3,361 shares during the period. Zoetis accounts for approximately 3.5% of Verde Servicos Internacionais S.A.’s portfolio, making the stock its 13th largest position. Verde Servicos Internacionais S.A.’s holdings in Zoetis were worth $7,590,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its stake in Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after buying an additional 3,244,074 shares during the last quarter. Global Assets Advisory LLC acquired a new position in shares of Zoetis in the 1st quarter valued at $8,831,000. Franklin Street Advisors Inc. NC raised its position in Zoetis by 4.3% in the 1st quarter. Franklin Street Advisors Inc. NC now owns 121,024 shares of the company’s stock valued at $20,478,000 after purchasing an additional 5,035 shares during the last quarter. Prevail Innovative Wealth Advisors LLC boosted its stake in Zoetis by 24.5% during the 1st quarter. Prevail Innovative Wealth Advisors LLC now owns 18,977 shares of the company’s stock worth $3,211,000 after purchasing an additional 3,738 shares during the period. Finally, Jacobi Capital Management LLC grew its position in Zoetis by 10.9% during the 4th quarter. Jacobi Capital Management LLC now owns 8,040 shares of the company’s stock worth $1,587,000 after purchasing an additional 788 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ZTS. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Piper Sandler boosted their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, Stifel Nicolaus increased their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Zoetis has a consensus rating of “Buy” and an average price target of $220.38.

Zoetis Trading Down 1.4 %

Shares of ZTS stock opened at $187.28 on Tuesday. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The business’s fifty day moving average price is $187.30 and its 200 day moving average price is $175.50. The firm has a market capitalization of $84.85 billion, a PE ratio of 36.08, a P/E/G ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business’s revenue was up 8.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.41 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.